Welcome to the Calico media center. Please find below features on our R&D efforts as well as our official press releases. For media inquiries, please email [email protected].
Calico and AbbVie’s Fosigotifator Selected for FDA’s New START Pilot Program Since 2015, Calico and the Broad Institute of MIT and Harvard have partnered to investigate the biology and genetics of aging and pursue early-stage drug discovery.
Cardiometabolic diseases are an increasing global health burden. And Calico scientists, led by Madeleine Cule, are working with the University of Westminster and … Keep Reading
In her role as Head of Project Team Leadership and Regulatory, Susan provides oversight and direction for Calico’s drug discovery and development programs as they transition from candidate nomination through IND filing and clinical proof of concept.
Calico registers interventional clinical trials conducted in patients on www.clinicaltrials.gov. If you are a patient interested in one of our clinical trials, please visit www.clinicaltrials.gov to learn more.
We are deliberate about creating a community in which Calico scientists and engineers have the freedom to explore, take chances and follow their own scientific pursuits and passions, wherever they may lead.
Mike joined Calico in 2024 as Chief Scientific Officer, a role in which he is responsible for the company’s overall research strategy. He is establishing a lab that will address the aging process and associated diseases, expanding upon his work in human genetics.
Calico employees are asking big questions about aging and age-related diseases. Life at Calico provides employees with the freedom and support to answer them, and then pursue their science all the way to the clinic.
Sandip leads Calico’s Software Engineering and Data Engineering teams, which comprise multidisciplinary scientist-engineers who collaborate with computational biologists, machine learning engineers, and lab scientists to ensure ready …